A Phase 2 interventional study of SOTATERCEPT (ACE-011) in Beta Thalassemia Major and Beta Thalassemia Intermedia, sponsored by Celgene. Terminated at 18 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-06-18.
Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in beta-Thalassemia by Bristol-Myers Squibb — 3 open to participants now, 5 under way, 1 of them phase 3. beta-Thalassemia · Bristol-Myers Squibb.
Among the 14 studies in beta-Thalassemia by Bristol-Myers Squibb, this one is the only one that started in 2012, is one of 4 in phase 2, and was the 3rd registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →3 of the 14 studies in beta-Thalassemia by Bristol-Myers Squibb are open now, in 12 countries. Recruiting first, the newest first:
Bristol-Myers Squibb · Sites in Korea, Republic of
Ages 19+
Celgene · Sites in United States, China, Germany and 6 more countries
Ages 6–17
Celgene · Sites in United States, Australia, Belgium and 19 more countries
Ages 18+
By country, each count listing its studies:
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2007; this study’s year is marked. 1 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 46 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 97 across the 8 interventional studies, 81 across the 6 observational. Of the 8 that completed or were terminated, 3 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Celgene, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.
Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in beta-Thalassemia by Bristol-Myers Squibb, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Dose finding study to determine the safety and tolerability of Sotatercept (ACE-011) in adults with Beta (β)-Thalassemia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For transfusion dependent subjects: permanent transfusion dependency is defined as requiring packed red blood cells (pRBCs) and iron chelation therapy:
No concurrent severe hepatic disease:
Exclusion Criteria:
Subjects with major cardiac problems such as:
A history of major organ damage including:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Experimental 0.1 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
Drug: SOTATERCEPT (ACE-011)
Experimental 0.3 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
Drug: SOTATERCEPT (ACE-011)
Experimental 0.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
Drug: SOTATERCEPT (ACE-011)
Experimental 0.75 mg/kg - Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
Drug: SOTATERCEPT (ACE-011)
Experimental 1.0 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
Drug: SOTATERCEPT (ACE-011)
Experimental 1.5 mg/kg -Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period
Drug: SOTATERCEPT (ACE-011)
0.1 mg/kg to 1.5mg/kg Sotatercept will be administered as a subcutaneous injection once every 21 days during the treatment period.
Also known as: (ACE-011)
Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose
Number of participants with dose-limiting toxicities (DLT) are used to determine the potential recommended dose (PRD). PRD is defined as the highest dose with up to 1 out of 6 patients experiencing a DLT. DLT is defined as any side effects of the study treatment serious enough to prevent an increase in dose or level of treatment, including at least one of the following: Hypertension ≥ Grade 3 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; Hgb \> 14 g/dL sustained for four weeks; any NCI CTCAE toxicity ≥ Grade 3. Grade 3 is defined as severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily life. PRD was identified as 1 mg/kg. Due to study termination, no patients were enrolled after 1 mg/kg cohort or in the Expansion Cohort. Thus, primary analyses to determine recommended dose (RD) were not conducted.
Time frame: From first dose up to 28 days post the first dose
Number of Participants With Red Blood Cell Transfusion Burden Reduction From Baseline During Treatment
Transfusion burden at baseline is defined as the total number of units of RBC transfusions that participants received within 168 days (24 weeks) prior to the first dose of study therapy. Transfusion burden during treatment is defined as the total number of RBC transfusion units that each participant received during the treatment divided by the treatment duration and multiplied by 168 days. The result is a 168-day transfusion burden average. Baseline measurement includes RBC transfusion history for transfusion dependent and non-transfusion dependent participants, starting at 168 days prior to enrollment.
Time frame: From baseline to the last dose of study treatment (up to approximately 112 months)
Number of Participants With Hemoglobin Level Increase From Baseline in Non-Transfusion Dependent B-Thalassemia Intermedia Participants
The Number of participants with a change in Hemoglobin levels will be listed for non-RBC transfusion dependent participants. Baseline assessments are the average of the last two measurements prior to the start of therapy.
Time frame: Measurements were taken in 9 and 12-week intervals, from baseline up to approximately 112 months
Number of Participants Experiencing Adverse Events (AEs)
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. Treatment emergent adverse events (TEAE) are defined as an AE that began after the start of trial medication treatment; or if the event was continuous from baseline and was serious, trial medication-related, or resulted in death, discontinuation, or interruption or reduction of trial therapy.
Time frame: From first dose up to 112 days after the last dose of study treatment (up to 115 months)
Concentrations of Sotatercept in Serum
Sotatercept was administered as a subcutaneous injection every 21 days during the Treatment Period. Pharmacokinetic (PK) samples were collected at the pre-specified timepoints.
Time frame: Dose 1, Day 8; Dose 1, Day 15; Dose 2, Day 1; Dose 2, Day 8; Dose 3, Day 1; Dose 3, Day 8; Dose 4, Day 1; Dose 5, Day 1; Dose 6, Day 1
Number of Participants With Anti-Drug Antibody (ADA)
The number of participants with Anti-Sotatercept Antibody is a summary of antidrug antibody (ADA) status for ADA-evaluated participants. A participant is counted as 'positive' if there is any positive result captured during the study, a participant is counted as 'negative' if there is no positive result captured during the study. ADA data was collected Day 1 in dose schedules 1 through 6. Starting from Dose 7, ADA was measured at Day 1 every 3 Doses, then finally at the post-treatment follow-up visit at Month 2 and Month 4.
Time frame: From first dose up to 4 months after last dose (up to approximately 116 months)
Number of Participants Experiencing Quality of Life (QOL) Change From Baseline
The number of participants in the expansion cohort experiencing changes from baseline in Quality of Life. QOL was planned to be assessed at Day 168 (6 months) and Day 336 (12 months), after Dose 1 Day 1, independent of Dose Delay for participants enrolled in the Expansion Cohort only. QOL was planned to be calculated using the SF-36 and the FACT Anemia. The SF-36 is a Medical Outcomes Study (MOS) consisting of 36 questions developed to determine health status. The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The FACT Anemia measures fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. Due to early study termination, no participants were enrolled in the expansion cohort and QOL was not assessed.
Time frame: From pre-dose up to Dose 8 (168 days/6months) and Dose 16 (336 days/12months) only
| Milestone | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| Started | 8 | 9 | 8 | 12 | 9 |
| Completed | 2 | 1 | 1 | 0 | 0 |
| Not completed | 6 | 8 | 7 | 12 | 9 |
| Withdrew: Adverse event | 3 | 0 | 2 | 3 | 5 |
| Withdrew: Other reasons | 2 | 1 | 2 | 2 | 1 |
| Withdrew: Study terminated by sponsor | 0 | 4 | 1 | 3 | 1 |
| Withdrew: Withdrew consent | 1 | 1 | 2 | 3 | 0 |
| Withdrew: Lack of efficacy | 0 | 2 | 0 | 1 | 2 |
Number of participants with dose-limiting toxicities (DLT) are used to determine the potential recommended dose (PRD). PRD is defined as the highest dose with up to 1 out of 6 patients experiencing a DLT. DLT is defined as any side effects of the study treatment serious enough to prevent an increase in dose or level of treatment, including at least one of the following: Hypertension ≥ Grade 3 per National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0; Hgb \> 14 g/dL sustained for four weeks; any NCI CTCAE toxicity ≥ Grade 3. Grade 3 is defined as severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self-care activities of daily life. PRD was identified as 1 mg/kg. Due to study termination, no patients were enrolled after 1 mg/kg cohort or in the Expansion Cohort. Thus, primary analyses to determine recommended dose (RD) were not conducted.
| Participants | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| Potential Recommended Dose as Determined by Number of Participants Experiencing Dose-Limiting Toxicities and Recommended Dose | 0 | 0 | 0 | 0 | 0 |
Transfusion burden at baseline is defined as the total number of units of RBC transfusions that participants received within 168 days (24 weeks) prior to the first dose of study therapy. Transfusion burden during treatment is defined as the total number of RBC transfusion units that each participant received during the treatment divided by the treatment duration and multiplied by 168 days. The result is a 168-day transfusion burden average. Baseline measurement includes RBC transfusion history for transfusion dependent and non-transfusion dependent participants, starting at 168 days prior to enrollment.
| Participants | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| ≥ 25% reduction | 0 | 0 | 2 | 4 | 3 |
| ≥ 33% reduction | 0 | 0 | 2 | 3 | 1 |
| ≥ 50% reduction | 0 | 0 | 1 | 2 | 0 |
The Number of participants with a change in Hemoglobin levels will be listed for non-RBC transfusion dependent participants. Baseline assessments are the average of the last two measurements prior to the start of therapy.
| Participants | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| 9-week episode with Hgb ≥ 1.0 g/dl change from baseline (non-transfusion dependent participants) | 0 | 5 | 4 | 6 | 2 |
| 9-week episode with Hgb ≥ 1.5 g/dl change from baseline (non-transfusion dependent participants) | 0 | 2 | 2 | 6 | 1 |
| 12-Week episode with Hgb ≥ 1.0 g/dl change from baseline (non-transfusion dependent participants) | 0 | 4 | 4 | 6 | 1 |
| 12-Week episode with Hgb ≥ 1.5 g/dl change from baseline (non-transfusion dependent participants) | 0 | 2 | 2 | 6 | 1 |
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a pre-existing medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. Adverse events are graded on a scale from 1 to 5, with Grade 1 being mild and asymptomatic; Grade 2 is moderate requiring minimal, local or noninvasive intervention; Grade 3 is severe or medically significant but not immediately life-threatening; Grade 4 events are usually severe enough to require hospitalization; Grade 5 events are fatal. Treatment emergent adverse events (TEAE) are defined as an AE that began after the start of trial medication treatment; or if the event was continuous from baseline and was serious, trial medication-related, or resulted in death, discontinuation, or interruption or reduction of trial therapy.
| Participants | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| Participants with at least one TEAE | 8 | 9 | 8 | 12 | 9 |
| TEAE leading to dose interruption | 2 | 5 | 4 | 2 | 5 |
| Participants with at least one serious TEAE | 3 | 3 | 3 | 3 | 3 |
| Participants with at least one grade 2/3/4 TEAE | 7 | 9 | 6 | 11 | 9 |
| Participants with at least one drug-related grade 2/3/4 TEAE | 4 | 3 | 4 | 7 | 7 |
| Participants with at least one serious drug- related TEAE | 2 | 1 | 1 | 0 | 1 |
| Participants with at least one TEAE leading to sotatercept withdrawal | 3 | 0 | 2 | 3 | 5 |
Sotatercept was administered as a subcutaneous injection every 21 days during the Treatment Period. Pharmacokinetic (PK) samples were collected at the pre-specified timepoints.
| ng/mL | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| Dose 1, Day 8 | 598.3 (289.2 to 1345.4) | 1454.05 (1006.6 to 2768.3) | 3045.45 (1586.7 to 4480) | 5837.65 (3238.1 to 10590.5) | 3874 (2264.9 to 7003) |
| Dose 1, Day 15 | 388.7 (98.4 to 1046) | 1150.1 (550.3 to 2158.4) | 2329.75 (952 to 3005.5) | 4279.65 (2107.8 to 6692) | 2405.6 (1825.3 to 4605.5) |
| Dose 2, Day 1 | 294.75 (112.9 to 547.1) | 770.3 (317.2 to 1300.1) | 1468.05 (682 to 2550.5) | 2955.2 (1257.5 to 4450.8) | 1701.5 (888.6 to 4267.9) |
| Dose 2, Day 8 | 683.1 (250.1 to 1210.6) | 2065 (1363.7 to 3626.4) | 4136.8 (1661.9 to 5573.8) | 7753.35 (5046.4 to 8805.6) | 5148.1 (3537.4 to 10418.7) |
| Dose 3, Day 1 | 325.35 (228.8 to 790) | 956.8 (380.6 to 1552.6) | 2157.3 (422 to 3088.4) | 3628.45 (653.5 to 6429.1) | 2602.6 (822.2 to 5668.1) |
| Dose 3, Day 8 | 758.1 (444 to 1232) | 2319.9 (1475.6 to 3667.4) | 4507.3 (2077.8 to 5762.3) | 8373.05 (5345.5 to 12177.8) | 6050.8 (3892.5 to 12139.6) |
| Dose 4, Day 1 | 334.85 (298 to 1014.9) | 1022.3 (348.8 to 2096.9) | 2441.6 (784 to 2845.3) | 4137.1 (1447.1 to 6126.6) | 2869.2 (1478.9 to 4787.7) |
| Dose 5, Day 1 | 385.1 (287.5 to 467.5) | 1473.9 (762.1 to 2764.4) | 1618.8 (953.4 to 3440) | 4449.7 (2340.4 to 5887.8) | 3048 (1125.5 to 6529.3) |
| Dose 6, Day 1 | 297.60 (227.80 to 484.40) | 1368.10 (449.70 to 2363.20) | 2266.40 (1115.20 to 3788.50) | 4062.80 (1481.10 to 6584.00) | 2780.80 (1479.20 to 7896.70) |
The number of participants with Anti-Sotatercept Antibody is a summary of antidrug antibody (ADA) status for ADA-evaluated participants. A participant is counted as 'positive' if there is any positive result captured during the study, a participant is counted as 'negative' if there is no positive result captured during the study. ADA data was collected Day 1 in dose schedules 1 through 6. Starting from Dose 7, ADA was measured at Day 1 every 3 Doses, then finally at the post-treatment follow-up visit at Month 2 and Month 4.
| Participants | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| Negative | 8 | 8 | 8 | 10 | 9 |
| Positive | 0 | 1 | 0 | 2 | 0 |
The number of participants in the expansion cohort experiencing changes from baseline in Quality of Life. QOL was planned to be assessed at Day 168 (6 months) and Day 336 (12 months), after Dose 1 Day 1, independent of Dose Delay for participants enrolled in the Expansion Cohort only. QOL was planned to be calculated using the SF-36 and the FACT Anemia. The SF-36 is a Medical Outcomes Study (MOS) consisting of 36 questions developed to determine health status. The SF-36 measures eight scales: physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional, and mental health. The FACT Anemia measures fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) Measurement System. Due to early study termination, no participants were enrolled in the expansion cohort and QOL was not assessed.
No measurements were reported for this outcome.
Collected over Participants were assessed for all-cause mortality from their enrollment to study completion, (up to approximately 115 months). SAEs and Other AEs were assessed from first dose to 112 days following last dose (up to approximately 115 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Level 1a: 0.1 mg/kg | 0/8 (0%) | 3/8 (37.5%) | 8/8 (100%) |
| Dose Level 1b: 0.3 mg/kg | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| Dose Level 2: 0.5 mg/kg | 0/8 (0%) | 3/8 (37.5%) | 8/8 (100%) |
| Dose Level 3: 0.75 mg/kg | 0/12 (0%) | 3/12 (25%) | 12/12 (100%) |
| Dose Level 4: 1 mg/kg | 0/9 (0%) | 3/9 (33.3%) | 9/9 (100%) |
| Event | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| ANAEMIABlood and lymphatic system disorders | 0/8 | 0/9 | 1/8 | 0/12 | 0/9 |
| SPLENIC INFARCTIONBlood and lymphatic system disorders | 1/8 | 0/9 | 0/8 | 0/12 | 0/9 |
| PERICARDIAL EFFUSIONCardiac disorders | 0/8 | 0/9 | 1/8 | 0/12 | 0/9 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 0/8 | 0/9 | 1/8 | 0/12 | 0/9 |
| FATIGUEGeneral disorders | 0/8 | 0/9 | 1/8 | 0/12 | 0/9 |
| LOCAL SWELLINGGeneral disorders | 0/8 | 0/9 | 1/8 | 0/12 | 0/9 |
| PYREXIAGeneral disorders | 0/8 | 1/9 | 1/8 | 0/12 | 0/9 |
| ANAPHYLACTIC REACTIONImmune system disorders | 0/8 | 0/9 | 1/8 | 0/12 | 0/9 |
| LUMBAR VERTEBRAL FRACTUREInjury, poisoning and procedural complications | 0/8 | 0/9 | 1/8 | 0/12 | 0/9 |
| BONE PAINMusculoskeletal and connective tissue disorders | 1/8 | 0/9 | 0/8 | 0/12 | 0/9 |
| Event | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg |
|---|---|---|---|---|---|
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 5/8 | 6/9 | 7/8 | 8/12 | 2/9 |
| BACK PAINMusculoskeletal and connective tissue disorders | 3/8 | 7/9 | 6/8 | 5/12 | 3/9 |
| HEADACHENervous system disorders | 2/8 | 6/9 | 5/8 | 9/12 | 3/9 |
| PYREXIAGeneral disorders | 3/8 | 6/9 | 2/8 | 3/12 | 4/9 |
| BONE PAINMusculoskeletal and connective tissue disorders | 4/8 | 6/9 | 4/8 | 4/12 | 4/9 |
| RHINITISInfections and infestations | 1/8 | 3/9 | 5/8 | 1/12 | 1/9 |
| PAIN IN EXTREMITYMusculoskeletal and connective tissue disorders | 3/8 | 3/9 | 5/8 | 5/12 | 3/9 |
| COUGHRespiratory, thoracic and mediastinal disorders | 3/8 | 4/9 | 5/8 | 3/12 | 3/9 |
| ABDOMINAL PAIN UPPERGastrointestinal disorders | 2/8 | 5/9 | 1/8 | 4/12 | 1/9 |
| INFLUENZAInfections and infestations | 0/8 | 5/9 | 1/8 | 1/12 | 1/9 |
| Age, Continuous(Years) | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg | Total |
|---|---|---|---|---|---|---|
| Median | 39.5 ± 8.21 | 40.0 ± 9.89 | 38.5 ± 7.63 | 44.0 ± 10.29 | 41.0 ± 10.36 | 39.5 ± 9.22 |
| Sex: Female, Male(Participants) | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg | Total |
|---|---|---|---|---|---|---|
| Female | 4 | 4 | 3 | 8 | 3 | 22 |
| Male | 4 | 5 | 5 | 4 | 6 | 24 |
| Race (NIH/OMB)(Participants) | Dose Level 1a: 0.1 mg/kg | Dose Level 1b: 0.3 mg/kg | Dose Level 2: 0.5 mg/kg | Dose Level 3: 0.75 mg/kg | Dose Level 4: 1 mg/kg | Total |
|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 2 | 1 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 | 0 |
| White | 7 | 9 | 6 | 10 | 8 | 40 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 2 | 0 | 0 | 2 |
Ran from Oct 2012 to primary completion in Jul 2015, 32 months.
Results were first posted in Jun 2023, 7 years 11 months after primary completion. A results delay was requested in Dec 2015.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sotatercept